Research Papers:

A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants

Lin Song, Cui-Yao He, Nan-Ge Yin, Fang Liu, Yun-Tao Jia _ and Yao Liu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:105211-105221. https://doi.org/10.18632/oncotarget.22114

Metrics: PDF 776 views  |   HTML 1266 views  |   ?  


Lin Song1, Cui-Yao He1, Nan-Ge Yin1, Fang Liu2, Yun-Tao Jia1 and Yao Liu2

1Department of Pharmacy, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Children’s Hospital of Chongqing Medical University, Chongqing 400014, China

2Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing 400038, China

Correspondence to:

Yun-Tao Jia, email: jiayuntaocqykdx@sina.com

Yao Liu, email: swhliuyao@163.com

Keywords: vancomycin; Chinese young infants; population pharmacokinetics; phoenix NLME

Received: August 30, 2017    Accepted: September 23, 2017    Published: October 26, 2017


Population pharmacokinetic (PPK) modelling is an easy and impartment method for estimating drug concentration for use inindividualized therapy, especially for young patients and to help protect drug-induced diseases. The purpose of this study was to develop a PPK model for effective dosing of vancomycin in Chinese neonates and young infants. The PPK modelling tool Phoenix® NLME™ was use to assess demographic and routine clinical pharmacokinetic (PK) data retrospectively collected for patients admitted to Children’s Hospital of Chongqing Medical University between 2011 and 2016. Data of patients admitted to the hospital between January and June of 2017 were used in validation study, and the final model was also preliminary validated in 2 cases in another hospital. A total of 421 serum samples from 316 patients were included in the initial PPK analysis. A two-compartment PPK model was developed, and exponential-error model was used to describe inter-individual variability of clearance. Residual variability was described by an additive model. The final PPK model was demonstrated as valid by internal and external model evaluation. Of note, the clearance and volume of vancomycin in Chinese neonates and young infants may be greater than in Caucasians. Herein, we describe the establishment of an accurate PPK model of vancomycin for Chinese neonates and young infants, which may be useful as a dosing algorithm for this particular paediatric population.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22114